



# International Thoracic Surgical Oncology Summit



September 27–28, 2024  
Sheraton New York Times Square  
New York, NY, USA

## **Industry-Supported Symposia**

**Friday, September 27, 2024  
7:30-8:15AM**

### **Alecensa (alectinib) - New Indication based on Results from the Phase III ALINA Study**

*Sponsored by: Genentech, a member of the Roche Group*

Empire East Room

Speaker: Jay Lee, University of California Los Angeles

This session will provide a comprehensive overview of Alecensa and the indication in ALK positive NSCLC based on the Phase III ALINA study results. Attendees will gain insights into the study design, efficacy and safety and the clinical significance of Alecensa in reducing the risk of disease recurrence or death in ALK positive NSCLC patients.

**Friday, September 27, 2024  
12:30-1:15PM**

### **Sublobar Resection for NSCLC: Right Patient, Right Resection, Right Approach**

*Sponsored by: Medtronic*

Empire East Room

Moderator: Bernard Park, Memorial Sloan Kettering Cancer Center

Speakers:

Nasser Altorki, New York Presbyterian-Weill Cornell Medical Center

Mark Onaitis, University of California San Diego

Kazuhiro Yasufuku, University of Toronto

Panel discussion on the decision-making process and technical considerations in sublobar resection for NSCLC. The panelists will examine approaches in complex surgical cases and discuss their insights.

### **Integrating Immunotherapy in Resectable NSCLC:**

#### **How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways**

*Supported by: AstraZeneca, Bristol Myers Squibb, and Merck and Co., Inc.*

*CME provided by: PVI, PeerView Institute for Medical Education*

[Sign up link](#)

Metropolitan East Room

Speakers:

Jessica Donington, University of Chicago

Jonathan Spicer, McGill University

In this PeerView Live “Modern Practice Principles in Action” CME symposium, experts will analyze the latest practice-changing data on neoadjuvant, adjuvant, and perioperative immunotherapy in resectable NSCLC, along with implications for practice. In addition, they will demonstrate how to improve multidisciplinary alliances and facilitate the incorporation of immunotherapy into new standards of care through open discussions and real-world case scenarios.

**Friday, September 27, 2024**  
**6:45-7:15PM**

**Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC: Collaborative Workflows and Personalized Solutions for Integration of Adjuvant EGFR- and ALK-Targeted Therapies**

*Supported by: AstraZeneca and Genentech, a member of the Roche Group*

*CME provided by: PVI, PeerView Institute for Medical Education*

[Sign up link](#)

Metropolitan East Room

Speakers:

Ibiayi Dagogo-Jack, Harvard Medical School

Jay Lee, UCLA Health

This PeerView Live MasterClass & Practicum symposium will explore the expanding role of biomarker testing and EGFR- or ALK-targeted therapies in stage I-III resectable NSCLC. Through interpretations of the latest evidence and discussion of real-world patient cases, experts will demonstrate how to improve alliances, collaboration, and workflows among the members of the multidisciplinary team to identify targetable genomic alterations such as EGFR mutations and ALK fusions, develop customized multimodal treatment plans inclusive of adjuvant targeted therapies, and improve outcomes in early-stage lung cancer.

**Saturday, September 28, 2024**  
**7:15-8:00AM**

**Segmentectomy vs Lobectomy – Has the Paradigm Shifted?**

*Sponsored by: Johnson & Johnson MedTech*

Empire East Room

Moderator: Paul Morris, Sr. Director of Medical Affairs, Johnson & Johnson

Speakers:

Faiz Bhora, Hackensack Meridian Health

Daniela Molena, Memorial Sloan Kettering Cancer Center

Our panel of distinguished thoracic surgeons will discuss how technology and the latest research is causing thoracic surgeons to re-think lung resection surgery.

**Saturday, September 28, 2024**  
**12:00-12:45PM**

**Thoracic Oncology with the Intuitive Ecosystem: Learn how Ion and da Vinci 5 may enable better efficiencies and help lower the total cost of care.**

*Sponsored by: Intuitive Surgical*

Metropolitan East Room

Speakers:

Robert Merritt, Ohio State University

Elliot Servais, Lahey Clinic

Join Intuitive for an exploration of the role the da Vinci 5 and the Ion by Intuitive platforms are playing to shape the lung care continuum. Drs. Elliot Servais and Robert Merritt explore procedures in depth and highlight the value features like Force Feedback, Case Insights and Intuitive Telepresence can bring to your practice.

**A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)**

*Sponsored by: Merck & Co., Inc.*

Empire East Room

Speaker: Bryan Payne Stanifer, Columbia University Irving Medical Center

The learning objectives of this session are: Review and understand the disease state and the role of the multidisciplinary team; understand how patient characteristics may influence your treatment plan; and, review approved indication and clinical data supporting a treatment option for patients with resectable NSCLC.